Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC (Venture Capital) Funds in Israel in November 2024

Last updated: Nov 2024 A list of 50 VC (Venture Capital) funds that invest in Life science startups based in Israel. We rank investors based on the number of investments they made in Life science companies from Israel. We update this investor list every month.

Top 50 Life Science VC (Venture Capital) Funds in Israel in November 2024

Investor	Life Science Israel investments
Integra Holdings	4
Sapir Venture Partners	4
OrbiMed	3
Pitango VC	3
Neo Ventures	3
Israel Innovation Authority	3
Johnson & Johnson Robotics and Digital Solutions	2
Cancer Focus Fund	2
aMoon Fund	2
SOSV	2
FutuRx	2
PeakBridge	2
Genesis Park	2
First Star Ventures	2
Pontifax	2
Minrav	2
fresh.fund	2
Grove Ventures	2
Takeda Ventures	2
Arancia International	2
Forbion Capital Partners	1
Talisman Capital Partners	1
Windham Venture Partners	1
Office of the Chief Scientist	1
SICAR	1
Aries Holding BV	1
3B Future Health Fund	1
Arkin Holdings	1
Remiges Ventures	1
Life Science Angels	1
HBL Hadasit Bio Holdings	1
RM Global Partners	1
Trendlines Group	1
OTV	1
Stony Hill Corp	1
Dementia Discovery Fund	1
Arix Bioscience	1
NextLeap Ventures	1
TPY Capital	1
Arc Impact	1
Jerusalem Venture Partners (JVP)	1
Rationalwave Capital Partners	1
Bio Capital Impact Fund	1
Sectoral Asset Management	1
Angel	1
Arba Finance Ltd.	1
Milk and Honey Investments	1
Pfizer	1
M Ventures	1
Boehringer Ingelheim Venture Fund	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with

Investment focus

Biotechnology, Pharmaceutical, Life Science
Seed, Series B, Series F
Israel

Portfolio highlights

BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
Splisense — Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried.
Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria

Early Stage VC

Investment focus

Software, Biotechnology, Machine Learning
Seed, Pre-Seed, Series A
Israel, United States, United Kingdom

Portfolio highlights

Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

enGene — enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expressionlevels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Leal Therapeutics — Leal Therapeutics develops novel therapeutics for patients.
Lomond Therapeutics — Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies.

Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.

Investment focus

Software, Health Care, Information Technology
Series A, Series B, Series C
Israel, United States, China

Portfolio highlights

Guardoc Health — Streamlining clinical compliance with AI-driven accuracy in charting to meet regulations, enhance patient care, and optimize revenue management.
Quantum Source — Quantum Source is on a clear path to the most powerful, cost-effective, practical photonic quantum computer. Learn more.
Magenta Medical — Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.

Neo Ventures is the first open-ended early stage investor, based in Eastern Europe. The founders have backed more than 30 startups and exited 10 successfully. We invest in game-changing businesses, without geographic limitations. We partner with exceptional founder teams to challenge incumbents in markets ripe for change or to create entirely newmarkets. Neo Ventures funds and then supports the founders in business planning, scaling operations, follow-on investments, making the best of each opportunity and dealing with hard situations. Our investment focus is on data analytics, computer vision and remote sensing addressing disruptive opportunities across the high-growth SpaceTech, BioTech and Security verticals.

Investment focus

Software, Artificial Intelligence, Aerospace
Seed, Funding Round, Series A
Israel, United Kingdom, Estonia

Portfolio highlights

EnduroSat — At EnduroSat, we engineer, build and operate exceptional satellites. Our Mission is to make space universally accessible
Cyberwrite — TRUSTED BY INDUSTRY LEADERS One platform to accelerate value across the cyber insurance lifecycle THE LATEST FROM CYBERWRITE
GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.

Investment focus

Health Care, Medical Device, Biotechnology
Grant, Seed, Pre-Seed
Israel, United States, Mali

Portfolio highlights

Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
Lavie bio — Improve food quality, agricultural sustainability and productivity through the introduction of microbiome based ag-biological products.
Eretz Angels — Eretz Angels supports technology startups in Israel's outskirts at the start of their journey.

Healthcare innovation wherever it originates.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, United Kingdom

Portfolio highlights

Moon Surgical — MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.
Artera — Discover the power of Personalized Precision Medicine & AI Cancer Therapy with Artera. Transforming cancer therapy through innovation.
ONL Therapeutics — ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

Cancer Focus Fund is an investment firm that is dedicated to providing financial services to its clients. The company was founded by Ross Barrett.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Seed, Series A
Israel, United States, Germany

Portfolio highlights

Eisbach Bio — Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.

aMoon is a leading healthtech & life sciences venture capital firm.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Israel, Switzerland

Portfolio highlights

AltruBio — AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases.AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment ofcancer and immune-related inflammatory diseases.With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs.Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics.Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.
Air Doctor — Air Doctor provides a global medical network and makes it accessible for anyone looking for private medical care.
Eleos Health — Automate documentation, alleviate provider burnout, and elevate care quality with the CareOps Automation platform from Eleos Health.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.

Investment focus

Biotechnology, Life Science, Biopharma
Seed, Funding Round
Israel

Portfolio highlights

Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
Bsense Bio Therapeutics — Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.

PeakBridge is an Alternative Investment Fund Manager and Investment Services Firm specialized in FoodTech.

Investment focus

Food and Beverage, Food Processing, Health Care
Seed, Series A, Funding Round
Israel, United States, United Kingdom

Portfolio highlights

Mondra — AI-driven environmental insights platform that supports food system players to accelerate Scope 3 progress, reduce the cost of Net Zero, and drive competitive advantage.
WNWN Food Labs — We're WNWN Food Labs and we love food. We're creating delicious, sustainable and ethical alternatives to unsustainable and ethically dubious foods. We're starting with cacao-free chocolate. Changing chocolate? It's Win-Win #alt-chocolate #altchocolate #alt-universe #altuniverse #alt-protein
The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.

Genesis Park is a Houston-based private equity firm focusing on buyouts, partnering strategies with public corporations, and growth financing. We bring capital, commercial execution capabilities and a depth of experience in mergers and acquisitions.We are opportunistic within market sectors where we have depth and exposure. Those sectors includetelecommunications, energy technology and media. Energy technology is a rapidly expanding category, and our Houston base allows us to marry traditional and alternative techniques in upstream and downstream environments. Founded in 2000, Genesis Park has used discipline and patience to build value for our investors, regardless of prevailing market conditions. We are consistently active in our portfolio companies, listening, learning and adding value by working alongside management. While our preference is to partner with an existing management team, we commonly source additional talent to optimize the existing opportunity.

Investment focus

Manufacturing, Construction, Health Care
Private Equity, Debt Financing, Funding Round
United States, Israel

Portfolio highlights

The Good Feet Store — Discover comfort and foot pain relief with The Good Feet Store arch support inserts. Clinically proven - improve body alignment and overall foot health.
WESTCO GROUNDS — Westoco Provides Landscaping is a highly competitive industry, and Westco continues to thrive because it tailor services to specific client needs and deliver complete solutions with dependability,Rainbird facilitate quick responses and ressources.
Conditioned Air — Conditioned Air is South Florida's premier air conditioning contractor with 60 years of experience. Serving Naples, Venice, Ft. Myers, Englewood, Port Charlotte, Sarasota, Bradenton & Surrounding Areas.

Investing with conviction in visionary, technical founders inventing the future.

Investment focus

Software, Artificial Intelligence, Biotechnology
Seed, Pre-Seed, Series A
United States, Canada, Israel

Portfolio highlights

Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
Bot Auto — Bot Auto develops and operates autonomous trucks for middle-mile freight.
Phaseshift Technologies — Phaseshift Technologies is developing a Computational Materials Engineering (CME) platform to help accelerate the Research and Development of High-Performance Alloys. The CME platform is driven by Quantum Chemistry calculations and aided by Machine Learning based predictive algorithms.

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Minrav provides engineering and construction services.

Investment focus

Health Care, Hospital, Wellness
Series A, Funding Round
Israel, Malaysia

Portfolio highlights

iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
Qualitas Health — Qualitas Health Group aims to serve patients through a network of 500 clinics by 2022 with quality healthcare services across the Asia Pacific.

fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.

Investment focus

Health Care, FinTech, Education
Seed, Pre-Seed, Series A
Israel, United States, Norway

Portfolio highlights

enso — enso offers AI-powered bot bundles to automate your marketing strategy. Perfect for small business owners, our bots handle social media, SEO, lead generation & much more. Start with a 7 days free trial or talk with one of our marketing experts today.
Carbon Blue — Carbon Blue is developing an 'ocean-capture' scalable method for removing CO2 from the atmosphere. The company was founded by Iddo Tsur and Dan Deviri.
Guardoc Health — Streamlining clinical compliance with AI-driven accuracy in charting to meet regulations, enhance patient care, and optimize revenue management.

Grove Ventures is a leading early-stage venture capital fund in Israel. It partners early with exceptional Israeli founders who believe th...

Investment focus

Artificial Intelligence, Machine Learning, Software
Seed, Series A, Series B
Israel, United States

Portfolio highlights

Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
Wing Cloud — Wing Cloud tames cloud complexity through a unified programming and operational model that works across all providers and services.
Quantum Source — Quantum Source is on a clear path to the most powerful, cost-effective, practical photonic quantum computer. Learn more.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.

Investment focus

Health Care, Biotechnology, Life Science
Series A, Series B, Funding Round
Israel, United States, Malaysia

Portfolio highlights

NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.

Talisman Capital Partners operates as a private investment company.

Investment focus

Information Services, Pet, News
Series A, Seed, Series B
United States, Israel, Hong Kong

Portfolio highlights

Bond Vet — We offer compassionate, thorough, & friendly pet care in a warm, comfortable environment. Walk in or book online.
Prilenia — Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston.
qServe Communications — I found a great domain name for sale on Dan.com. Check it out!

We focus on advances in medical technology and digital health to change the face of healthcare.

Investment focus

Health Care, Medical, Biotechnology
Series B, Series C, Series A
United States, Israel

Portfolio highlights

SubjectWell — Connecting your trial or treatment to tens of millions of motivated patients with known conditions with global patient recruitment campaigns.
Alto Neuroscience — Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
Clever Care Health Plan Inc. — Clever Care delivers culturally sensitive Medicare options in Southern California that honor and represent the cultural values of the communities we serve. Health and wellness, centered around you.

The Office of the Chief Scientist [OCS] in the Ministry of Economy is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel’sscientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high tech entrepreneurship.

Investment focus

Health Care, Biotechnology, Hardware
Seed
Israel

Portfolio highlights

LapSpace — LapSpace Medical was founded in 2011. It operates within the framework of the Misgav Venture Accelerator, part of The Trendines Group. The LapSpace team combines strong business and medical experience and knowledge.
Digma Medical — Digma Medical | DiaGone - safe, one-time, 30 minute, minimaly-invasive, GI procedure for Restoring Glycemic Control for T2DM & NASH patients | No Implant
Immunovative Therapies — Immunovative Therapies is a biopharmaceutical company with financial support of the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world renown Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstandingincubator project of 2006, awarded by the Office of the Chief Scientist. They specialize in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for the treatment of cancer and infectious disease.

SICAR

Investment focus

Medical, Health Care, Life Science
Series C, Funding Round
Israel, Germany

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

financial holding company / investments

Investment focus

FinTech, Finance, Payments
Seed, Pre-Seed
The Netherlands, Israel

Portfolio highlights

Wakuli — It's called specialty coffee. Roasted lighter to enhance all the exciting flavours. To really taste them it's important to drink fresh. That's why we send our mailbox-friendly coffee within one week after roasting. And always with a better price for the farmers - thanks to you.
Diptera — Developing technology to fight mosquitoes with mosquitoes.
Flow — Flow is FinTech 3.0: It let's you automate payments between your bank accounts and wallets. Based on triggers and actions you can transfer your money automatically to the accounts you choose. Use Flow to automate a budgetting system, your investing, buying crypto or to distribute your money the way you like it. Where the previous generationpayment companies needed to build and maintain expensive payment rails, Flow focusses on leveraging Open Banking. People trust Flow to help with their cashflow automation.

Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.

Investment focus

Biotechnology, Therapeutics, Medical
Series B, Series A, Funding Round
United States, Italy, United Kingdom

Portfolio highlights

NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
On Target Laboratories — ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.

Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech, medical device, and digital health technologies. Our synergistic healthcare investments are focused on creating innovations that benefit humanity and enhance medical care. We offer extensive experience, with a track record of successful healthcareinvestments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth. Arkin Holdings currently has a healthcare portfolio of $1.5 billion through its 5 investment arms. Its investors include a substantial amount of Israel’s top-tier institutional investors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Seed, Funding Round
Israel, United States, Switzerland

Portfolio highlights

MadeRight — We usher in a new era of sustainable fungi-based materials that deliver excellent performance. The future, as we see it, is a novel industrial chain based on biomaterials.
Honeycomb — Honeycomb (fka Agilius) is the only place where you can buy a condo/apartment building master policy online in less than 3 minutes at a fraction of the cost! Instant, free, no hassle quotes, online everything and up to 40% savings. With all that we're bringing simplicity and transparency to the real estate insurance space for condoassociations (HOAs), building owners, property managers, and developers everywhere. This is what we do. This is all we do.
Nocion Therapeutics — Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation.

Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.

Investment focus

Biotechnology, Medical, Health Care
Series A, Series B, Seed
United States, Japan, Canada

Portfolio highlights

Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
Cyrano Therapeutics — Cyrano Therapeutics is the leader in Smell Loss therapy and smell loss research. Recover your sense of smell today!
Restore Vision — Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.

Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Seed, Series A
United States, Israel, The Netherlands

Portfolio highlights

Neurava — Neurava has developed wearable diagnostics for epilepsy patients including those at risk of SUDEP. The company specializes in the fields of medical device manufacturing, healthcare, and health diagnostics.
InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.

Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Series A, Series B
Israel

Portfolio highlights

ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.

RM Global is an investment banking and strategic advisory firm dedicated to creating unique value for its clients and investors. We specialize in Life Sciences, including pharmaceuticals, medical devices, biotechnology, healthcare IT/digital health, and diagnostics. Our broad international reach includes the Americas, Europe, Israel, and Asia.Since 1992, our diverse team of accomplished professionals has worked closely with life science companies ranging from start-ups to multinationals, providing unbiased strategic and financial advice, based upon our comprehensive industry experience. Several of our partners were senior management of Roberts Mitani, which completed over $3 billion in M&A and strategic transactions and raised over $200 million in private growth and venture capital for clients. We take pride in our long term relationships with our clients that span many years.We leverage our unique global network of leading corporations, investment funds, institutional and strategic investors, family offices, industry experts and management teams to source and execute transactions that build new opportunities for our clients worldwide.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B
Israel, United States

Portfolio highlights

BIOMx — Developing natural and engineered phage therapies to eradicate harmful bacteria in chronic diseases.
Mitoconix Bio — Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism,keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death.Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
ImmPACT Bio — ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Funding Round, Series A
Israel, Singapore, United Kingdom

Portfolio highlights

Insectta — Insectta was founded in 2017 and produces materials from insects which can be applied across industries such as agrifood, pharmaceutical and electronics.
Celleste Bio — Celleste is a business that specializes in employing cell culture techniques to produce high-value cocoa ingredients, removing the need for cocoa trees to be grown.
ViAqua Therapeutics — ViAqua is developing the first orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics.

OTV focuses on round A+ startups that aim to make a significant impact on people's lives. Our focus is on entrepreneurs with innovative ideas who are advancing the global state of well-being. Come join the digital health revolution, and be a part of transforming the healthcare industry.

Investment focus

Health Care, Medical, Artificial Intelligence
Series A, Series B, Seed
United States, Israel, Ghana

Portfolio highlights

Scopio — Buy & sell images on the largest Solana Photography NFT Marketplace. Find high-quality stock images & hire artists from around the world.
Scopio Labs — Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, toenable new hematology diagnostic methods.
Stake — Renters earn Cash back for rent. Building operators outperform the market. That's the Stake win-win. Find out how we're building the financial tools for the next generation of rentals.

A Diversified Company focused on multiple area of the cannabis hemp and CBD industry.

Investment focus

AgTech, Medical, Cannabis
Series A
Israel

Portfolio highlights

GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, France, Israel

Portfolio highlights

Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Disc Medicine — Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.

NextLeap Ventures offers investors the opportunity to invest in early stage, Israeli high-tech startups, selected through its unique, highly vetted process.

Investment focus

Software, Machine Learning, Health Care
Seed, Series A, Funding Round
Israel, United States

Portfolio highlights

Carrar — A complete thermal management solution for electric vehicles dissipating heat faster and more efficiently than ever before. Thermal management for ev batteries.
Cybord — Electronics components' quality, reliability, and highest level of traceability by leveraging visual AI and BigData
Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges

TPY Capital is a Tel Aviv based early state VC, investing in some of Israel’s most talented entrepreneurs. They are active investors who typically lead rounds in the areas we invest in, which include data and analytics, digitization and human augmentation, fintech, and frontier tech such as quantum computing.

Investment focus

Software, Artificial Intelligence, Big Data
Seed, Series A, Series B
Israel, United States, France

Portfolio highlights

Tabnine — Tabnine is an AI code-completion tool that helps developers worldwide write better code faster.
Kodem Security — Providing users with runtime intelligence to grasp the relevant application risks.
DOT Compliance — Dot Compliance offers the industry's first ready to use Quality Management Solution. Dot Compliance solutions include an extensive set of off-the-shelf ready eQMS and compliance pre-configured processes that include full project validation services and product validation packages. Introducing a true eQMS paradigm shift, Dot Compliance offersthe industry’s most cost-effective quality and compliance management solution available, allowing life science customers around the world to quickly deploy flexible and scalable solutions.

Arc Impact is a venture capital firm.

Investment focus

Health Care, Food and Beverage, AgTech
Seed, Pre-Seed
Israel, United States, United Kingdom

Portfolio highlights

Behavidence — Behavidence is a mental health application that generates a daily mental health score. It compares your digital behavior to other people with anxiety, depression and ADHD.
MadeRight — We usher in a new era of sustainable fungi-based materials that deliver excellent performance. The future, as we see it, is a novel industrial chain based on biomaterials.
Virtual Internships — The only platform that guarantees real-world work experience across the globe to shape tomorrow's workforce.

JVP is a top VC firm with $1.9B AUM and 165 companies built, leading in AI, Cyber Security, Fintech, Insurtech and Climatech.

Investment focus

Software, Cyber Security, Enterprise Software
Series A, Series B, Seed
United States, Israel, United Kingdom

Portfolio highlights

Datricks — Offering real-time risk detection and control, ensuring continuous financial compliance and enabling you to significantly impact the bottom line of your business
Greeneye Technology — Spray Less, Grow More. Our mission is to dramatically reduce chemicals usage while increasing productivity and profitability for farmers.
Secret Double Octopus — Provider of industry-leading FIDO-certified, rotation-based passwordless MFA with the fullest support for enterprise complexity. Click here for more!

Rationalwave Capital Partners is a venture capital firm investing in technology companies both public and private. The firm is located in New York and founded by Mark Rosenblatt in 2003.

Investment focus

Machine Learning, Artificial Intelligence, Analytics
Seed, Pre-Seed, Funding Round
United States, Israel, Trinidad and Tobago

Portfolio highlights

Aromyx — Aromyx pioneers the creation of tastes and smells using a quantitative measurement system developed with biotechnology, data science, and AI.
Brij — With one-touch, BRIJ allows consumers to gain product info, care instructions and discounts while you gain a deeper understanding of your consumer. Apps, paper manuals and hassles not required.
BactoByte LTD — BactoByte aims to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capability to improve outcomes, reduce mis-diagnostics, and lower health care costs.Based on a proprietary novel basic method, BactoByte’s assay delivers precise and cost-effective identification and direct antibiotics susceptibility testing with80-90% improvement of standard turnaround time.Time reduction, sensitivity, and specificity results in decreased mortality rates, fewer hospital days, and avoidance of associated costs of $1K-50K per patient.BactoByte has technology validation and partnerships with leading medical centers.

Global impact fund focusing on biotech, medtech and agritech investments that make a difference

Investment focus

Medical, Health Care, Life Science
Funding Round
Israel

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.

Sectoral is specialized in managing equities globally in the healthcare sector. Founded in October 2000, we are SEC-registered as an investment advisor. 100% employee-owned, we have offices in Montreal, Geneva, and Hong Kong.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Post-IPO Equity
United States, United Kingdom, France

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Phagenesis — Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.
LENZ Therapeutics — LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.

Angel

Investment focus

Software, Information Technology, Artificial Intelligence
Pre-Seed, Seed, Series A
United States, United Kingdom, Singapore

Portfolio highlights

Vytal.ai — Vytal allows for brain health evaluation in minutes with just a laptop. Take control of your cognitive health.
Akhetonics — Creating the first all-optical RISC Processor
Greena World — In a world where travel connects us, we often overlook the impact we leave behind. Tourism accounts for over 8% of global CO2 emissions. Beyond environmental challenges like deforestation, pollution, and water scarcity, local communities also face pressure, experiencing changes in their traditions and ways of life.With expertise from SwanseaUniversity and the United Nations, our team recognised these challenges and envisioned a world where travel helps, not harms. Introducing Greena World. More than just a piece of technology, it's a guide for hotels and restaurants, helping them understand, improve, and share their impact on both the environment and local communities.The true beauty of embracing sustainability? The rewards. With the Greena Index, businesses can improve their sustainability and, in doing so, unlock a new market of over 100+ million eco-conscious travellers, boost revenues, and save on operating costs.The sustainable tourism sector is rapidly expanding, currently valued at $75B and witnessing a growth rate of 9.7% each year. While our initial focus is on hotels and restaurants, the Greena Index has ambitions to reshape the entire spectrum of the industry, from airlines to activities and destinations.Join us on a mission to transform the entire tourism industry for many generations to come.

Investment banking boutique based in Tel Aviv since 1978.

Investment focus

AgTech, Medical, Cannabis
Series A
Israel

Portfolio highlights

GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

The Land of Milk and Honey is an abundant location where life is simple and devoid of need. Both in brand-new real estate development projects and while professionally restoring and renovating houses, Milk and Honey Investments LLC aims to create distinctive spaces of abundance and healthy living.

Investment focus

Life Science, Organic Food, Biotechnology
Series A
Israel

Portfolio highlights

BioBetter — BioBetter is a foodtech company that develops plant-based platforms for the production of complex growth factors used in cultivated meat. The company was founded in 2015 and is headquartered in Israel.

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Post-IPO Equity, Series A, Seed
United States, Israel, France

Portfolio highlights

CytoReason — CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases,reduce development costs and increase the likelihood of approval. To date, six of the world’s top ten pharma companies use CytoReason’s technology.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
PictorLabs — PictorLabs is a digital pathology company advancing AI-powered virtual staining technology to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence and health-tech product development, the Company is reimagining the ageold practice of histopathology. From a single unstained tissue sample, PictorLabs’ proprietary platform can sustainably produce an unlimited number of virtual stains that are indistinguishable from analogous chemical ones. PictorLabs' technology can replicate standard of care stains and perform specialized virtual biomarker stains for indications that require novel and accelerated diagnostic tests. To learn more, visit https://pictorlabs.ai/ and please follow PictorLabs on LinkedIn.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Investors by industry